Claudio Nessi
Président chez Calliditas Therapeutics Suisse SA
Profil
Dr. Claudio Nessi is a Managing Director at Omega Fund Management LLC, a Managing Partner at NeoMed S.à.r.l., a Chairman at Calliditas Therapeutics Suisse SA and a Chairman at Chord Therapeutics SA. He is on the Board of Directors at Anaconda Biomed SL, Avitide, Inc., CDR-Life Inc., Nuvation Bio Operating Co., Inc., SoniVie Ltd.
and NRG Therapeutics Ltd.
Dr. Nessi was previously employed as a Chairman by Calliditas Therapeutics France SAS, an Independent Director by Arsanis, Inc., a Non-Executive Director by Creabilis Holdings Ltd., a Venture Partner by Genevest Consulting Group SA, a Venture Partner by Genevest Consulting Group SA, and a Non-Executive Director by Creabilis Therapeutics Srl.
He also served on the board at Creabilis UK Ltd., ENDOSENSE SA, Axovan AG, Creabilis SA, EUSA Pharma, Inc., Kuros Biosurgery Holding AG and PregLem SA.
He received his graduate degree from the University of Lausanne, an MBA from Erasmus University Rotterdam and a doctorate degree from the University of Pavia.
Postes actifs de Claudio Nessi
| Sociétés | Poste | Début |
|---|---|---|
Calliditas Therapeutics Suisse SA
 Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | Président | - |
| NeoMed S.à.r.l. | Private Equity Investor | 01/03/2001 |
Avitide, Inc.
 Avitide, Inc. BiotechnologyHealth Technology Avitide, Inc. develops affinity purification solutions. Its technology enables development of chromatography resins via chemical synthesis which are not based on costly recombinant proteins. The company was founded by Errik B. Anderson, Warren Kett, Tillman U. Gerngross, Kevin Isett and Jonathan Sheller in 2012 and is headquartered in Lebanon, NH. | Directeur/Membre du Conseil | - |
Anaconda Biomed SL
 Anaconda Biomed SL Medical SpecialtiesHealth Technology Anaconda Biomed SL manufactures healthcare devices. It develops catheters for mechanical thrombectomies. The company was founded by Marc Ribo and Ofir Arad and is headquartered in Barcelona, Spain. | Directeur/Membre du Conseil | - |
Omega Fund Management LLC
 Omega Fund Management LLC Investment ManagersFinance Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US. | Private Equity Investor | 01/11/2016 |
Chord Therapeutics SA
 Chord Therapeutics SA BiotechnologyHealth Technology Chord Therapeutics SA is a clinical stage pharmaceutical company. It develops drugs for patients with rare, life-threatening and severely disabling diseases. The firm offers CRD1. The company was founded by Arthur Roach and is headquartered in Geneva, Switzerland. | Président | - |
Nuvation Bio Operating Co., Inc.
 Nuvation Bio Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Nuvation Bio Operating Co., Inc. engages in the provision of biotechnology company developing proprietary therapies focuse on oncology. It portfolio includes Seven Novel and Mechanistically Distinct Oncology Programs, Each with Multiple Drug Development Candidates. The company was founded by David Hung in 2018 and is headquartered in New York, NY. | Directeur/Membre du Conseil | - |
CDR-Life Inc.
 CDR-Life Inc. BiotechnologyHealth Technology CDR-Life Inc. is a Swiss biotherapeutics company that develops novel immunotherapies to target the power of the immune system specifically to tumor cells. CDR-Life is based in Schlieren, Switzerland, and was founded in 2017 by Leonardo Borras, Christian Leisner, Dominik Escher, Rouven Bingel-Erlenmeyer, and Konstantin von Schulthess. The company's proprietary antibody platform targets intracellular tumor antigens presented on the major histocompatibility complex (MHC) with high affinity and specificity, which allows them to develop a pipeline of first-in-class therapeutics across a broad range of solid tumors. The company is backed by leading cross-Atlantic investors and has an existing collaboration and licensing agreement with Boehringer Ingelheim for a novel antibody fragment therapy to treat macular degeneration. Christian Leisner has been the CEO since 2017. | Directeur/Membre du Conseil | - |
NRG Therapeutics Ltd.
 NRG Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services NRG Therapeutics Ltd. is a British neuroscience drug discovery company that focuses on building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson's and ALS. The company is based in Stevenage, UK, and was founded in 2018 by Neil Miller and Richard Rutter. The company's pre-clinical pipeline of small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mptp) through a novel mechanism of action. Inhibition of the mptp has been shown to protect neurons, reduce neuroinflammation, and extend survival in pre-clinical disease models. Neil Miller has been the CEO since 2018. | Directeur/Membre du Conseil | - |
| ░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Anciens postes connus de Claudio Nessi
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░░░░ ░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░░░░ ░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
Formation de Claudio Nessi
| Erasmus University Rotterdam | Masters Business Admin |
| University of Pavia | Doctorate Degree |
| University of Lausanne | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 22 |
|---|---|
PregLem SA
 PregLem SA Pharmaceuticals: MajorHealth Technology PregLem SA manufactures and markets pharmaceutical products specializing in gynecology and women's reproductive health. Its products include ESMYA, PGL2001, and PGL1001. The company was founded in June 2006 and is headquartered in Geneva, Switzerland. | Health Technology |
Creabilis Therapeutics Srl
 Creabilis Therapeutics Srl Pharmaceuticals: MajorHealth Technology Creabilis Therapeutics SRL discovers, develops, and markets prescription medicines to treat skin disease. Its products include CT200 and CT335, which is used to treat Behcet's disease; and CT327, which is used for the treatment of psoriasis, atopic dermatitis, and overgrowth of keratinocytes. The company’s products also include CT400, which is used for developing inhibitors of HGMB-1; and CT500 for the treatment of inflammatory disorders. The company was founded by Alfredo Boni in 2003 and is headquartered in Colleretto Giacosa, Italy. | Health Technology |
Kuros Biosurgery Holding AG
 Kuros Biosurgery Holding AG Miscellaneous Commercial ServicesCommercial Services Kuros Biosurgery Holding AG operated as a medical technology company. It engaged in the development of biologic and biomaterial-based product candidates for localized therapy in trauma, spine and wound care. The company was founded by Marion Bavand, Didier Cowling, Dominik Ellenrieder, and Jeffrey Hubbel on April 3, 2008 and was headquartered in Zurich, Switzerland. | Commercial Services |
Axovan AG
 Axovan AG Miscellaneous Commercial ServicesCommercial Services Axovan AG conducts biopharmaceutical research and develops pharmaceuticals. Active in pharmaceutical research and development, it focuses on the family of drug targets called G protein-coupled receptors (GPCRs), which are involved in a number of pathologies. It has developed a validated GPCR-based chemical library through its proprietary chem-informatics platform AXADDIS. Its lead product, clasozentan, is an intravenous endothelin receptor antagonist optimized for treating cerebral diseases. It is partnering non-core indication projects (pain, metabolic diseases, inflammation) at earlier stages. The company was founded in 2000 and is headquartered in Allschwil, Switzerland. | Commercial Services |
ENDOSENSE SA
 ENDOSENSE SA Medical SpecialtiesHealth Technology Endosense SA operated as a medical technology company, which focused on reproducibility of catheter ablation for the treatment of cardiac arrhythmias. The firm's flagship product was TactiCath Quartz that helped physicians to measure contact force during the catheter ablation procedure. The company was founded by Vitali Verin, Giovanni Leo, and Nicolas Aeby in 2003 and was headquartered in Geneva, Switzerland. | Health Technology |
REFERENCE CAPITAL SA
 REFERENCE CAPITAL SA Investment ManagersFinance Genevest Consulting Group SA is an independent Swiss venture capital firm which was founded in 1983 to provide advisory services to institutional investors and high-net worth individuals. Based in Geneva, Genevest operates in close cooperation with Endeavour Vision SA. | Finance |
Creabilis Holdings Ltd.
 Creabilis Holdings Ltd. Pharmaceuticals: MajorHealth Technology Creabilis Holdings Ltd. operates as a biotechnology company. The company was founded on June 7, 2013 and is headquartered in Canterbury, the United Kingdom. | Health Technology |
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | Health Technology |
Arsanis, Inc.
 Arsanis, Inc. BiotechnologyHealth Technology Arsanis, Inc. operates as a clinical-stage biotechnology company, which engages in provision of monoclonal antibody immunotherapies to address serious infectious diseases. The company was founded by Eszter Nagy, Tillman U. Gerngross, and Errik B. Anderson on August 2, 2010 and is headquartered in Waltham, MA. | Health Technology |
EUSA Pharma, Inc.
 EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | Health Technology |
| NeoMed S.à.r.l. | Finance |
Calliditas Therapeutics France SAS
 Calliditas Therapeutics France SAS Pharmaceuticals: MajorHealth Technology Calliditas Therapeutics France SAS is a biopharmaceutical company, which engages in the NOX therapies. Its therapeutic approach is based on a selective inhibition of NOX enzymes that amplify multiple disease processes, such as fibrosis, inflammation, pain processing, cancer development, and eurodegeneration. The firm’s platform enables the identification of orally available small molecules that selectively inhibit specific NOX enzymes. The company was founded in 2006 and is headquartered in Saint-Julien-en-Genevois, France. | Health Technology |
Creabilis UK Ltd.
 Creabilis UK Ltd. BiotechnologyHealth Technology Part of Sienna Biopharmaceuticals, Inc., Creabilis UK Ltd. engages in research and development of biological products. The company is based in Canterbury, UK. | Health Technology |
Avitide, Inc.
Avitide, Inc. BiotechnologyHealth Technology Avitide, Inc. develops affinity purification solutions. Its technology enables development of chromatography resins via chemical synthesis which are not based on costly recombinant proteins. The company was founded by Errik B. Anderson, Warren Kett, Tillman U. Gerngross, Kevin Isett and Jonathan Sheller in 2012 and is headquartered in Lebanon, NH. | Health Technology |
Anaconda Biomed SL
Anaconda Biomed SL Medical SpecialtiesHealth Technology Anaconda Biomed SL manufactures healthcare devices. It develops catheters for mechanical thrombectomies. The company was founded by Marc Ribo and Ofir Arad and is headquartered in Barcelona, Spain. | Health Technology |
| Creabilis SA | |
Omega Fund Management LLC
Omega Fund Management LLC Investment ManagersFinance Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US. | Finance |
Chord Therapeutics SA
Chord Therapeutics SA BiotechnologyHealth Technology Chord Therapeutics SA is a clinical stage pharmaceutical company. It develops drugs for patients with rare, life-threatening and severely disabling diseases. The firm offers CRD1. The company was founded by Arthur Roach and is headquartered in Geneva, Switzerland. | Health Technology |
Nuvation Bio Operating Co., Inc.
Nuvation Bio Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Nuvation Bio Operating Co., Inc. engages in the provision of biotechnology company developing proprietary therapies focuse on oncology. It portfolio includes Seven Novel and Mechanistically Distinct Oncology Programs, Each with Multiple Drug Development Candidates. The company was founded by David Hung in 2018 and is headquartered in New York, NY. | Health Technology |
CDR-Life Inc.
CDR-Life Inc. BiotechnologyHealth Technology CDR-Life Inc. is a Swiss biotherapeutics company that develops novel immunotherapies to target the power of the immune system specifically to tumor cells. CDR-Life is based in Schlieren, Switzerland, and was founded in 2017 by Leonardo Borras, Christian Leisner, Dominik Escher, Rouven Bingel-Erlenmeyer, and Konstantin von Schulthess. The company's proprietary antibody platform targets intracellular tumor antigens presented on the major histocompatibility complex (MHC) with high affinity and specificity, which allows them to develop a pipeline of first-in-class therapeutics across a broad range of solid tumors. The company is backed by leading cross-Atlantic investors and has an existing collaboration and licensing agreement with Boehringer Ingelheim for a novel antibody fragment therapy to treat macular degeneration. Christian Leisner has been the CEO since 2017. | Health Technology |
NRG Therapeutics Ltd.
NRG Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services NRG Therapeutics Ltd. is a British neuroscience drug discovery company that focuses on building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson's and ALS. The company is based in Stevenage, UK, and was founded in 2018 by Neil Miller and Richard Rutter. The company's pre-clinical pipeline of small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mptp) through a novel mechanism of action. Inhibition of the mptp has been shown to protect neurons, reduce neuroinflammation, and extend survival in pre-clinical disease models. Neil Miller has been the CEO since 2018. | Commercial Services |
SoniVie Ltd.
 SoniVie Ltd. Medical SpecialtiesHealth Technology SoniVie Ltd. engages in the development of a system for the treatment of pulmonary hypertension. Its products include Therapeutic Intra-Vascular Ultrasound (TIVUS) system, an intravascular, catheter-based technology that can cause denervation of nerves surrounding blood vessels and other structures like the bronchus. The company was founded by Moshe Arkin in 2014 and is headquartered in Rosh Haayin, Israel. | Health Technology |
